134 related articles for article (PubMed ID: 37881488)
21. ErbB4-encoded novel miRNAs act as tumor suppressors by regulating ErbB/PI3K signaling.
Ghaemi Z; Soltani BM; Mowla SJ
Tumour Biol; 2022; 44(1):215-230. PubMed ID: 36442170
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-936 Targets FGF2 to Inhibit Epithelial Ovarian Cancer Aggressiveness by Deactivating the PI3K/Akt Pathway [Retraction].
Onco Targets Ther; 2021; 14():4961-4962. PubMed ID: 34675537
[TBL] [Abstract][Full Text] [Related]
23. Retraction: Ppm1b Negatively Regulates 3-Bromopyruvic Acid Induced Necroptosis in Breast Cancer Cells.
Frontiers Editorial Office
Front Oncol; 2021; 11():757083. PubMed ID: 34513719
[TBL] [Abstract][Full Text] [Related]
24. MiR-126 Regulates Proliferation and Invasion in the Bladder Cancer BLS Cell Line by Targeting the PIK3R2-Mediated PI3K/Akt Signaling Pathway [Retraction].
Onco Targets Ther; 2021; 14():1859. PubMed ID: 33732003
[TBL] [Abstract][Full Text] [Related]
25. Retraction: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
Frontiers Editorial Office
Front Oncol; 2020; 10():714. PubMed ID: 32373542
[TBL] [Abstract][Full Text] [Related]
26. Retraction: Emodin interferes with AKT1-mediated DNA damage and decreases resistance of breast cancer cells to doxorubicin.
Frontiers Editorial Office
Front Oncol; 2023; 13():1337635. PubMed ID: 38130993
[TBL] [Abstract][Full Text] [Related]
27. Retraction: RBFOX3 Promotes Gastric Cancer Growth and Progression by Activating HTERT Signaling.
Frontiers Editorial Office
Front Oncol; 2021; 11():738970. PubMed ID: 34532292
[TBL] [Abstract][Full Text] [Related]
28. Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway.
Frontiers Editorial Office
Front Oncol; 2021; 11():707608. PubMed ID: 34136414
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-761 Targets FGFR1 to Suppress the Malignancy of Osteosarcoma by Deactivating PI3K/Akt Pathway [Retraction].
Onco Targets Ther; 2021; 14():4937-4938. PubMed ID: 34611413
[TBL] [Abstract][Full Text] [Related]
30. Retraction: AnnexinA5 might suppress the phenotype of human gastric cancer cells via ERK pathway.
Frontiers Editorial Office
Front Oncol; 2023; 13():1294881. PubMed ID: 37841426
[TBL] [Abstract][Full Text] [Related]
31. Retraction: lncRNA-XLOC_012370 Promotes the Development of Pancreatic Cancer and Inactivates the NF-κB Pathway Through miR-140-5p.
Frontiers Editorial Office
Front Oncol; 2021; 11():841478. PubMed ID: 35036363
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-423 Drug Resistance and Proliferation of Breast Cancer Cells by Targeting ZFP36 [Retraction].
Onco Targets Ther; 2022; 15():469-470. PubMed ID: 35535169
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-21 Contributes to Cutaneous Squamous Cell Carcinoma Progression via Mediating TIMP3/PI3K/AKT Signaling Axis [Retraction].
Int J Gen Med; 2023; 16():5159-5160. PubMed ID: 37954653
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA 628 Suppresses Migration and Invasion of Breast Cancer Stem Cells through Targeting SOS1 [Retraction].
Onco Targets Ther; 2023; 16():421-422. PubMed ID: 37359350
[TBL] [Abstract][Full Text] [Related]
35. microRNA-605 Directly Targets SOX9 to Alleviate the Aggressive Phenotypes of Glioblastoma Multiforme Cell Lines by Deactivating the PI3K/Akt Pathway [Retraction].
Onco Targets Ther; 2021; 14():4739-4740. PubMed ID: 34526778
[TBL] [Abstract][Full Text] [Related]
36. Retraction: The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer.
Frontiers Editorial Office
Front Oncol; 2024; 14():1383383. PubMed ID: 38450197
[TBL] [Abstract][Full Text] [Related]
37. Retraction: RORα Suppresses Epithelial-to-Mesenchymal Transition and Invasion in Human Gastric Cancer Cells via the Wnt/β-Catenin Pathway.
Frontiers Editorial Office
Front Oncol; 2020; 10():607586. PubMed ID: 33194774
[TBL] [Abstract][Full Text] [Related]
38. Retraction: CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer.
Frontiers Editorial Office
Front Oncol; 2021; 11():694036. PubMed ID: 34041039
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-937 Inhibits the Malignant Phenotypes of Breast Cancer by Directly Targeting and Downregulating Forkhead Box Q1 [Retraction].
Onco Targets Ther; 2021; 14():4991-4992. PubMed ID: 34675539
[TBL] [Abstract][Full Text] [Related]
40. Retraction: Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 Through the Wnt Signaling Pathway.
Pathol Oncol Res; 2021; 27():1609917. PubMed ID: 34321960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
